BiomX Announces Dual Listing on the Tel-Aviv

BiomX Announces Dual Listing on the Tel-Aviv

- Tel Aviv Stock Exchange trading effective February 6th,

- BiomX common shares will continue to trade on the NYSE under the symbol PHGE

Ness Ziona, Israel -

February 3rd , 2020 - BiomX Inc. (NYSE: PHGE), a clinical-stage biotechnology

company developing both natural and engineered phage therapies, today announced that the Tel Aviv Stock Exchange (TASE) has approved

the listing of its common shares, with trading effective February 6th, 2020.

The Company's common shares will continue to trade on

the NYSE American Stock Market, and the Company will continue to comply with the reporting and disclosure requirements of the U.S.

Securities and Exchanges Commission, without any additional regulatory requirements.

"We are excited to begin trading on the Tel Aviv Stock

Exchange in Israel, the country in which we were founded and are headquartered," said BiomX CEO Jonathan Solomon. "We

are proud to provide another route for Israeli investors to participate in our growth as a leading developer of targeted phage

products. We particularly look forward to disclosing Phase 1 data for our lead acne program by the end of the first quarter of

2020 and Phase 1 data for our inflammatory bowel disease program in the second half of 2020."

Ittai Ben Zeev, CEO of TASE, congratulated BiomX for

joining the Tel Aviv Stock Exchange as a dual listed company. He added, "We believe that it is important that any Israeli

company traded abroad, also has access to the Israeli capital markets. Dual listing in Tel Aviv has many advantages for the Company

and for the investors, including access to additional potential investors, and to additional trading days and hours, as well as

entry into the leading indices on TASE, which would contribute to increased tradability of, and liquidity in, the shares."

Bacteriophage, or phage, are viruses

that target bacteria and are considered inert to mammalian cells. Phage are designed to target and kill specific bacterial species

or strains without disrupting other bacteria or the healthy microbiota. All of BiomX's phage-based product candidates derive

from its proprietary platform, which is first used to discover and validate the association of specific bacterial strains with

human diseases or conditions, and is then used to develop rationally-designed phage combinations ("cocktails") of

naturally occurring or synthetic phage to target pathogenic bacteria. The phage cocktails contain multiple phage with complementary

functions optimized through in vitro and in vivo testing.

BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and

destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel

disease (IBD), primary sclerosing cholangitis (PSC), and colorectal cancer (CRC). BiomX discovers and validates proprietary bacterial

targets and customizes phage compositions against these targets.

Safe Harbor Language

This press release contains certain

"forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities

Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe,"

"expect," "will," "may," "anticipate," "estimate," "would,"

"positioned," "future," and other similar expressions that predict or indicate future events or trends

or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future

performance. Instead, they are based only on BiomX management's current beliefs, expectations and assumptions. Because forward-looking

statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult

to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated

in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. You should review

additional disclosures we make in our filings with the Securities and Exchange Commission (the "SEC"), which are available

on the SEC's website at www.sec.gov.

Chief Business Officer